~~<i id='3ACC6EA2E9'><strike id='3ACC6EA2E9'><tt id='3ACC6EA2E9'><pre id='3ACC6EA2E9'></pre></tt></strike></i>~~

Home» Wikipedia» focus

focus

author：knowledge 2025-10-01 01:54:04 Page View：5832

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How dance can help nurses traumatized by Covid
Next article： Anesthesiologist group: stop taking Ozempic before surgery

leisure time

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Custom gene therapy hints at new path for rare disease treatments

AdobeWhenTimothyYudevelopedmilasen,acustomdrugforayounggirlnamedMilawithBattendisease,heignitedaspar

Duchenne breakthrough therapy leaves behind pioneering families

DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

Hubble vs. James Webb telescope images: See the difference

2:22NASA'sJamesWebbSpaceTelescoperevealsStephan'sQuintetinanewlight.Avisualgroupingoffivegalaxies,is

WSS

focus

focus

explore

leisure time

Hubble vs. James Webb telescope images: See the difference